ArticleBiology open2026
Drug repurposing to combat multidrug-resistant hookworm.
Article in Biology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Anthelmintic resistance (AR) poses an escalating threat to global soil-transmitted helminth control efforts, particularly in the context of mass drug administration (MDA) programs that rely heavily on benzimidazole drugs. To address the urgent need for novel therapeutics, a machine learning (ML) guided drug repurposing pipeline was developed to identify compounds effective against a multi-anthelmintic drug-resistant (MADR) isolate of Ancylostoma caninum. The computational strategy employed in this work involved training classifiers on curated datasets of anthelmintic actives and decoys, followed by screening all approved drugs from the online database, DrugBank. Selected compounds were tested using a tiered assay system comprising egg hatch assays (EHA), larval development assays (LDA), and adult survival assays. Among these, flutamide, a nonsteroidal antiandrogen approved for prostate cancer, demonstrated potent, egg- and larval-stage-specific activity against MADR hookworm. Flutamide exhibited a concentration-dependent inhibition of egg hatching and arrested larval development in MADR hookworm. These findings underscore the translational value of drug repurposing to accelerate therapeutic discovery against MADR helminths.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.